These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1168 related articles for article (PubMed ID: 25828391)
21. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma. Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538 [TBL] [Abstract][Full Text] [Related]
22. Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics. Turakhia SK; Hill BT; Dufresne SD; Nakashima MO; Cotta CV Am J Clin Pathol; 2014 Sep; 142(3):339-46. PubMed ID: 25125624 [TBL] [Abstract][Full Text] [Related]
23. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations? Mationg-Kalaw E; Tan LH; Tay K; Lim ST; Tang T; Lee YY; Tan SY Histopathology; 2012 Dec; 61(6):1214-8. PubMed ID: 23171357 [TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma. Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646 [TBL] [Abstract][Full Text] [Related]
25. Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL. Dunleavy K Curr Treat Options Oncol; 2015 Dec; 16(12):58. PubMed ID: 26634708 [TBL] [Abstract][Full Text] [Related]
26. Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens. Kim H; Kim HJ; Kim SH Ann Lab Med; 2020 Sep; 40(5):361-369. PubMed ID: 32311849 [TBL] [Abstract][Full Text] [Related]
27. "Triple hit" lymphomas: A retrospective cytology case series of an uncommon high grade B-cell malignancy with C-MYC, BCL-2 and BCL-6 rearrangements. Eldessouki T; Hanley K; Hamadeh F; Oshilaja OO; Sturgis CD Diagn Cytopathol; 2018 Sep; 46(9):807-811. PubMed ID: 30043475 [TBL] [Abstract][Full Text] [Related]
28. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384 [TBL] [Abstract][Full Text] [Related]
29. Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome. Gualco G; Weiss LM; Harrington WJ; Bacchi CE Am J Surg Pathol; 2009 Dec; 33(12):1815-22. PubMed ID: 19816150 [TBL] [Abstract][Full Text] [Related]
30. MYC rearranged B-cell neoplasms: Impact of genetics on classification. Haberl S; Haferlach T; Stengel A; Jeromin S; Kern W; Haferlach C Cancer Genet; 2016 Oct; 209(10):431-439. PubMed ID: 27810071 [TBL] [Abstract][Full Text] [Related]
31. Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases. Pina-Oviedo S; Bellamy WT; Gokden M Ann Diagn Pathol; 2020 Oct; 48():151610. PubMed ID: 32889391 [TBL] [Abstract][Full Text] [Related]
32. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895 [TBL] [Abstract][Full Text] [Related]
33. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches. Petrich AM; Nabhan C; Smith SM Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588 [TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234 [TBL] [Abstract][Full Text] [Related]
35. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes. Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S J BUON; 2015; 20(3):820-8. PubMed ID: 26214636 [TBL] [Abstract][Full Text] [Related]
36. Translocation (3;8)(q27;q24) in two cases of triple hit lymphoma. Motlló C; Grau J; Juncà J; Ruiz N; Mate JL; Orna E; Navarro JT; Vives S; Sancho JM; Esteban D; Granada I; Feliu E; Ribera JM; Millá F Cancer Genet Cytogenet; 2010 Dec; 203(2):328-32. PubMed ID: 21156254 [TBL] [Abstract][Full Text] [Related]
37. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma. Rosenthal A; Younes A Blood Rev; 2017 Mar; 31(2):37-42. PubMed ID: 27717585 [TBL] [Abstract][Full Text] [Related]
39. Molecular characterization of a rare case of high-grade B-cell lymphoma with MYC, BCL2, BCL6, and CCND1 rearrangements. Monika F; Sabri A; Cantu D; Vail E; Siref A J Hematop; 2024 Sep; 17(3):155-161. PubMed ID: 38914869 [TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Akyurek N; Uner A; Benekli M; Barista I Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]